Epilepsy – Landscape & Forecast – Disease Landscape & Forecast
Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The epilepsy therapy market already comprises more than 25 antiepileptic drugs (AEDs), most of them generic, that can be effective for many patients. In this challenging market environment, developers increasingly target underserved, niche segments or subpopulations (e.g., orphan pediatric syndromes, rescue therapy) as a path to differentiation. Understanding the trajectory of the established epilepsy market and the evolving competitive landscape in niche segments is critical for marketers of both current and emerging brands to retain market share or carve out a clinical role.
Questions Answered:
- What is the current state of treatment in epilepsy in the G7, and what needs are left unfulfilled by approved AEDs?
- What are the market opportunities and sales potential for agents targeting treatment-refractory focal epilepsy (e.g., Xcopri) and for agents targeting orphan epilepsy subpopulations (e.g., Epidiolex, Fintepla)?
- What clinical role will recently approved and emerging acute rescue therapies (e.g., Nayzilam, Valtoco, Libervant) play in the epilepsy market?
- How will neurologists differentiate between current and emerging third-generation AEDs, and which of these agents will experience the most clinical and commercial success in the face of strong generics competition from first- and second-generation AEDs?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 27 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other DRG research.
Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.
Emerging therapies: Phase III/PR: 5 drugs; coverage of select Phase II products.
Market forecast features: Patient-based market forecast extending through 2029, segmented by brands/generics.
Key companies: Aquestive Therapeutics, Bial, Eisai, Eton Pharmaceuticals, GW Pharmaceuticals, Lundbeck, Marinus Pharmaceuticals, Neurelis, Sanofi, SK Biopharmaceuticals, UCB, Sunovion, Zogenix.
Key drugs: Levetiracetam, lamotrigine, carbamazepine, valproates, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), Fycompa (perampanel), Briviact (brivaracetam), Epidiolex / Epidyolex (cannabidiol), Fintepla (fenfluramine), Xcopri (cenobamate), Nayzilam (intranasal midazolam), Libervant (buccal diazepam), Valtoco (intranasal diazepam).
Solution Enhancement:
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Epilepsy - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Q4 2021
- October 2021
- Q3 2021
- September 2021
- August 2021
- July 2021
- Q2 2021
- June 2021
- May 2021
- April 2021
- Q1 2021
- March 2021
- February 2021
- January 2021
- Q4 2020
- November 2020
- Q4 2021
- Key Findings
- Epilepsy - Key Findings - January 2021
- November 2020
- Epilepsy - Key Findings - January 2021
- Market Outlook
- Key Findings
- Market Share of Drug Classes for Epilepsy: 2019
- Market Share of Drug Classes for Epilepsy: 2029
- Epilepsy SWOT Analysis
- COVID-19: Areas of Potential Forecast Impact
- Market Drivers and Constraints
- What Factors Are Driving the Market for Epilepsy?
- What Factors Are Constraining the Market for Epilepsy?
- Major-Market Sales by Class in Epilepsy: 2019-2029
- Major-Market Patient Share by Class in Epilepsy: 2019-2029
- Total Sales by Region in Epilepsy: 2019-2029
- Major-Market Sales of Emerging Therapies for Epilepsy: 2019-2029
- Drug-Class-Specific Trends
- Major-Market Sales of First-Generation AEDs in Epilepsy: 2019-2029
- Major-Market Patient Share of Key First-Generation AEDs in Epilepsy: 2019-2029
- Major-Market Sales of Second-Generation AEDs in Epilepsy: 2019-2029
- U.S. Patient Share of Key Second-Generation AEDs in Epilepsy: 2019-2029
- European Patient Share of Key Second-Generation AEDs in Epilepsy: 2019-2029
- Japanese Patient Share of Key Second-Generation AEDs in Epilepsy: 2019-2029
- Major-Market Sales of Third-Generation AEDs in Epilepsy: 2019-2029
- U.S. Patient Share of Key Third-Generation AEDs in Epilepsy: 2019-2029
- European Patient Share of Key Third-Generation AEDs in Epilepsy: 2019-2029
- Japanese Patient Share of Key Third-Generation AEDs in Epilepsy: 2019-2029
- Major-Market Sales of Rescue Therapies in Epilepsy: 2019-2029
- U.S. Patient Share of Rescue Therapies in Epilepsy: 2019-2029
- European Patient Share of Rescue Therapies in Epilepsy: 2019-2029
- Japanese Patient Share of Rescue Therapies in Epilepsy: 2019-2029
- Key Findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease Overview
- Classification of Seizures and Epilepsies
- Widely Used Classification of Key Types of Seizure by Clinical Presentation
- 2017 ILAE Classification of Types of Seizure by Clinical Presentation
- Examples of Epilepsies and Syndromes Classified by Type of Seizure and Etiology
- Etiology
- Genes Implicated in the Etiology of Key Epilepsies and Epilepsy Syndromes
- Symptomatic Factors Implicated in the Etiology of Epilepsy
- Pathophysiology
- Neuronal Signaling from the Presynaptic to the Postsynaptic Neuron
- Key Pathways and Drug Targets
- Key Pathways and Drug Targets in Epilepsy
- Disease Overview
- Epidemiology
- Key Findings
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Prevalent Cases of Epilepsy
- Diagnosed Prevalent Cases of Epilepsy: 2020-2030 (thousands)
- Diagnosis of Epilepsy
- Disease Definition
- Methods
- Sources Used for Type of Epileptic Seizure
- Diagnosed Prevalent Cases by Type of Epileptic Seizure: 2020-2030 (thousands)
- Drug-Treated Diagnosed Prevalent Cases of Epilepsy: 2019-2029 (thousands)
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Epilepsy
- Key Current Therapies
- Overview
- Primary Mechanism of Action of Key Current Drugs Used for Epilepsy
- Current Treatments Used for Epilepsy
- U.S. and European Approvals of Key Current Therapies by Type of Seizure
- Market Events Impacting the Use of Key Current Therapies in Epilepsy
- Advantages and Disadvantages of First-Generation AEDs
- Expert Insight: Use of First-Generation AEDs in the Treatment of Epilepsy
- Advantages and Disadvantages of Second-Generation AEDs
- Expert Insight: Use of Second-Generation AEDs in the Treatment of Epilepsy
- Advantages and Disadvantages of Lacosamide
- Ongoing Clinical Development of Lacosamide
- Expert Insight: Lacosamide
- Advantages and Disadvantages of Eslicarbazepine Acetate
- Expert Insight: Eslicarbazepine Acetate
- Advantages and Disadvantages of Perampanel
- Ongoing Clinical Development of Perampanel
- Expert Insight: Perampanel
- Advantages and Disadvantages of Pregabalin
- Expert Insight: Pregabalin
- Advantages and Disadvantages of Brivaracetam
- Ongoing Clinical Development of Brivaracetam
- Expert Insight: Brivaracetam
- Advantages and Disadvantages of Cenobamate
- Ongoing Clinical Development of Cenobamate
- Expert Insight: Cenobamate
- Advantages and Disadvantages of Rufinamide
- Expert Insight: Rufinamide
- Advantages and Disadvantages of Cannabidiol
- Expert Insight: Cannabidiol
- Advantages and Disadvantages of Stiripentol
- Expert Insight: Use of Stiripentol in the Treatment of Epilepsy
- Advantages and Disadvantages of Fenfluramine
- Ongoing Clinical Development of Fenfluramine
- Expert Insight: Fenfluramine
- Advantages and Disadvantages of Outpatient Rescue Therapies
- Expert Insight: Outpatient Rescue Therapies
- Medical Practice
- Overview
- Country-Specific Epilepsy Treatment Guidelines
- Factors Influencing Drug Selection in Epilepsy
- Treatment Decision Tree for Epilepsy: United States
- Treatment Decision Tree for Epilepsy: Europe
- Treatment Decision Tree for Epilepsy: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Epilepsy
- Top Unmet Needs in Epilepsy: Current and Future Attainment
- Emerging Therapies
- Key Findings
- Key Emerging Therapies
- Key Therapies in Development for Epilepsy
- Estimated Launch Dates of Key Emerging Therapies for the Treatment of Epilepsy
- ET-105 (Lamotrigine Oral Suspension) Profile
- Expectations for Launch and Sales Opportunity of ET-105 (Lamotrigine Oral Suspension) in Epilepsy
- ET-104 (Zonisamide Oral Suspension) Profile
- Expectations for Launch and Sales Opportunity of ET-104 (Zonisamide Oral Suspension) in Epilepsy
- ET-101 (Topiramate Oral Solution) Profile
- Expectations for Launch and Sales Opportunity of ET-101 (Topiramate Oral Solution) in Epilepsy
- Ganaxolone Profile
- Analysis of the Clinical Development Program for Ganaxolone
- Expectations for Launch and Sales Opportunity of Ganaxolone in Epilepsy
- Libervant Profile
- Analysis of the Clinical Development Program for Libervant
- Expert Insight: Libervant
- Expectations for Launch and Sales Opportunity of Libervant in Epilepsy
- Early-Phase Pipeline Analysis
- Select Compounds in Phase II Development for Epilepsy
- Key Findings
- Access & Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Access Considerations in Epilepsy: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Epilepsy: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Epilepsy: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Key Abbreviations Related to Epilepsy
- Brands, Marketers, and Generic Availability of Key Therapies for Epilepsy by Market
- Epilepsy Bibliography
- Key Updates
Jonathan W. Searles is a senior director on the CNS/Ophthalmology Disorders team at Clarivate. In this role, he oversees the team’s syndicated research stream in neurology, with a core focus on multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy, migraine, and ischemic stroke. He earned his bachelor’s degree at Brandeis University, where he graduated summa cum laude.
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.